Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fosun Pharma

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Research Partnership

- PMLiVE

Takeda’s once-weekly DPP-4 inhibitor cleared in first market

Zafatek’s authorisation one of a flurry of new approvals for a number of firms in Japan

Eli Lilly HQ

Lilly signs cancer pact with Chinese biotech

Marks first major deal between a Western pharma company and a Chinese biotech

- PMLiVE

GSK fires Chinese staff over corruption charges

110 employees reportedly dismissed for misconduct

Takeda appoints Christophe Weber as its new CEO

Frenchman had been widely expected to succeed Yasuchika Hasegawa

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

Novartis building

Novartis’ Japanese subsidiary threatened with suspension

Company failed to report more than 3,200 adverse events among patients taking its drugs

- PMLiVE

GSK set ‘to cut 1,000 jobs’ in China

Pharma company's troubles in the country reportedly continue

China flag thumb

China approves home-grown polio vaccine

Country clamps down on recent outbreaks of disease

Daiichi Sankyo logo

Daiichi Sankyo pays $39m in whistleblower case

Accused of paying US doctors to prescribe its drugs

Daiichi Sankyo logo

Daiichi’s novel anticoagulant Savaysa cleared in US

Approval comes more than three years after it was approved in Japan

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links